Commentary: Adverse event profiles of PARP inhibitors: analysis of spontaneous reports submitted to FAERS

Jeanne M Schilder; Amanda Golembesky; Tirza Areli Calderón Boyle; Gui Lan Ye; Judi Kuplast

doi:10.3389/fphar.2023.1241524

Commentary: Adverse event profiles of PARP inhibitors: analysis of spontaneous reports submitted to FAERS

Front Pharmacol. 2023 Aug 16:14:1241524. doi: 10.3389/fphar.2023.1241524. eCollection 2023.

Authors

Jeanne M Schilder¹, Amanda Golembesky², Tirza Areli Calderón Boyle³, Gui Lan Ye³, Judi Kuplast³

Affiliations

¹ GSK, Philadelphia, PA, United States.
² GSK, Durham, NC, United States.
³ GSK, Collegeville, PA, United States.

No abstract available

Keywords: FAERS; PARP inhibitors; lymphangioleiomyomatosis; niraparib; pharmacovigilance.

Publication types

Comment

Grants and funding

This general commentary article was supported by GSK. GSK was involved in the study design, data collection and analysis, general commentary preparation, and the decision to publish the general commentary.